HK Stock Market Move | ABBISKO-B(02256) up more than 4% in the closing session, the company has recently been continuously repurchasing shares, and it is expected to submit a global NDA for Pimintinib.

ABBISKO-B (02256) rose more than 4% in the final trading session, up 3.78% as of the time of writing, at 8.24 Hong Kong dollars, with a turnover of 232.68 million Hong Kong dollars. On the news front, HeYu has recently been conducting continuous buybacks. On May 14th, the company once again spent 2.756 million Hong Kong dollars to repurchase 347,000 shares. Ping An Securities pointed out that HeYu achieved full-year profitability for the first time in 2024, and in 2025 the company will launch a new round of stock buyback plan not exceeding 200 million Hong Kong dollars, further enhancing shareholder value, and once again demonstrating the management team's strong confidence in the future development prospects of the company. Haitong International released a research report stating that in 2024, HeYu's full-year revenue was 504 million yuan, a year-on-year increase of over 25 times, with the revenue increase mainly coming from the authorization agreement for Pimicotinib (CSF-1R) in Greater China area with Merck, a $70 million upfront payment, and $1 million milestone revenue from Shanghai Allist Pharmaceuticals Co., Ltd. The net profit reached 28.3 million yuan. The company currently has abundant cash reserves, with a cash and bank balance of 1.96 billion yuan as of December 31, 2024. The company achieved annual profitability for the first time in 2024. In 2025, the company's core pipeline drug, Pimicotinib, is expected to submit a global NDA, with commercialization on the horizon.